Sugi Predict

Sugi Predict / Compounds / SCHEMBL19209562

SCHEMBL19209562

SCHEMBL19209562

O=Cc1c(F)cc(Br)cc1Cl

nearest known ligand 0.37

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 2/20 0.37
▸ KMT2A Q03164 2/20 0.37
▸ ALDH1A1 P00352 2/20 0.37
▸ TDP1 Q9NUW8 1/20 0.37
▸ NMT1 P30419 1/20 0.36
▸ ERN1 O75460 2/20 0.31
▸ ACLY P53396 2/20 0.31
▸ OPRM1 P35372 1/20 0.31
▸ OPRD1 P41143 1/20 0.31
▸ LMNA P02545 1/20 0.30
▸ MAPT P10636 1/20 0.30
▸ HTT P42858 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30975524 1.00 MEN1 (0.37) MEN1KMT2AALDH1A1TDP1NMT1
SCHEMBL2429712 0.84 ALDH1A1 (0.50) MEN1KMT2AALDH1A1TDP1NMT1
SCHEMBL578367 0.84 ERN1 (0.37) ALDH1A1ERN1
SCHEMBL23603879 0.79 NMT1 (0.32) NMT1
SCHEMBL15543777 0.79 ALDH1A1 (0.37) MEN1KMT2AALDH1A1TDP1ERN1
SCHEMBL6060504 0.78 ERN1 (0.42) MEN1KMT2AALDH1A1TDP1ERN1
SCHEMBL9712527 0.78 ERN1 (0.42) MEN1KMT2AALDH1A1TDP1ERN1
SCHEMBL29824002 0.78 ERN1 (0.42) MEN1KMT2AALDH1A1TDP1ERN1
SCHEMBL1591899 0.78 ERN1 (0.42) ALDH1A1TDP1ERN1
SCHEMBL27702448 0.77 ALDH1A1 (0.45) MEN1KMT2AALDH1A1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117964466-A Synthesis [13Method for preparing C4-bromo-2-chloro-6-fluoro-benzaldehyde 长沙贝塔医药科技有限公司 2024-05-03 — — CN claimed
US-20260138978-A1 POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M1 VANDERBILT UNIV (US) 2026-05-21 — — US disclosed
US-12503468-B2 Heterocyclic compound, intermediate, preparation method therefor and application thereof WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) 2025-12-23 — — US disclosed
US-12497382-B2 GLP-1R modulating compounds GILEAD SCIENCES, INC. (US) 2025-12-16 — — US disclosed
US-12479849-B2 EGFR inhibitors for the treatment of cancer HOFFMANN-LA ROCHE INC. (US) 2025-11-25 — — US disclosed
EP-4648851-A1 SUBSTITUTED (HETERO)ANILINES AND THEIR USE Astrazeneca AB (SE) 2025-11-19 — — EP disclosed
CN-119874674-A GLP-1R modulating compounds 吉利德科学公司 2025-04-25 — — CN disclosed
WO-2025067111-A1 MENIN-MLL INTERACTION INHIBITOR AND PREPARATION METHOD THEREFOR, AND APPLICATION 苏州必扬医药科技有限公司 2025-04-03 — — WO disclosed
CN-114630823-B GLP-1R Modulating Compounds 吉利德科学公司 2025-01-28 — — CN disclosed
US-12187736-B2 Selective estrogen receptor degraders and uses thereof INVENTISBIO LLC (US) 2025-01-07 — — US disclosed
CN-111777593-A Novel compounds as inhibitors of rearrangement kinase during transfection 南京天印健华医药科技有限公司 2020-10-16 — — CN disclosed
WO-2020135771-A1 HETEROCYCLIC COMPOUND INTERMEDIATE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF 武汉朗来科技发展有限公司 2020-07-02 — — WO disclosed
WO-2020135771-A1 HETEROCYCLIC COMPOUND INTERMEDIATE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF 武汉朗来科技发展有限公司 2020-07-02 — — WO disclosed
US-10647724-B2 Selective estrogen receptor degraders and uses thereof INVENTISBIO INC. (KY) 2020-05-12 — — US disclosed
US-20200048250-A1 SELECTIVE ESTROGEN RECEPTOR DEGRADERS AND USES THEREOF INVENTISBIO LLC 2020-02-13 — — US disclosed
US-20200040001-A1 SELECTIVE ESTROGEN RECEPTOR DEGRADERS AND USES THEREOF INVENTISBIO LLC 2020-02-06 — — US disclosed
EP-3411034-A1 SELECTIVE ESTROGEN RECEPTOR DEGRADERS AND USES THEREOF Inventisbio Inc. (KY) 2018-12-12 — — EP disclosed
WO-2018145021-A1 ATAZANAVIR (ATV) ANALOGUES FOR TREATING HIV INFECTIONS GILEAD SCIENCES, INC. (US) 2018-08-09 — — WO disclosed
WO-2017136688-A1 SELECTIVE ESTROGEN RECEPTOR DEGRADERS AND USES THEREOF INVENTISBIO INC. (KY) 2017-08-10 — — WO disclosed
WO-2017136688-A1 SELECTIVE ESTROGEN RECEPTOR DEGRADERS AND USES THEREOF INVENTISBIO INC. (KY) 2017-08-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200048250-A1 SELECTIVE ESTROGEN RECEPTOR DEGRADERS AND USES THEREOF ESR1, ESRRA, ESR2 MEN1 3338/4885KMT2A 1662/4885ALDH1A1 413/4885
US-12187736-B2 Selective estrogen receptor degraders and uses thereof ESR1, ESRRA, ESR2 MEN1 3338/4885KMT2A 1662/4885ALDH1A1 413/4885
US-12503468-B2 Heterocyclic compound, intermediate, preparation method therefor and application thereof P2RX3, P2RX7, P2RX4 MEN1 1165/4885KMT2A 4633/4885ALDH1A1 996/4885
US-20260138978-A1 POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M1 CHRM1, CHRM4, CHRM2 MEN1 3137/4885KMT2A 1457/4885ALDH1A1 1029/4885
US-10647724-B2 Selective estrogen receptor degraders and uses thereof ESR1, ESRRA, ESR2 MEN1 3338/4885KMT2A 1662/4885ALDH1A1 413/4885
US-20200040001-A1 SELECTIVE ESTROGEN RECEPTOR DEGRADERS AND USES THEREOF ESR1, ESRRA, ESR2 MEN1 3338/4885KMT2A 1662/4885ALDH1A1 413/4885
US-12479849-B2 EGFR inhibitors for the treatment of cancer EGFR, ERBB2, ERBB3 MEN1 4510/4885KMT2A 3229/4885ALDH1A1 4090/4885
US-12497382-B2 GLP-1R modulating compounds GLP1R, GIPR, GPR119 MEN1 1966/4885KMT2A 3870/4885ALDH1A1 3556/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.